uniQure
Pioneering gene therapy, uniQure develops transformative treatments using its AAV-based technology platform. They achieved a landmark approval for their hemophilia B gene therapy, marking a significant advancement in genomic medicine. Building on this success, uniQure is advancing clinical programs for Huntington’s disease and developing a pipeline of preclinical candidates. Orignally spunout as Amsterdam Molecular Therapeutics […]
DCPrime
Pioneering cancer vaccines, DCPrime leverages its DCOne® dendritic cell technology to develop innovative immunotherapies. Their lead candidate, DCP-001, is currently in a Phase 2 study for Acute Myeloid Leukemia (AML), building on promising Phase 1 results. With Orphan Medicinal Product designation in the EU, DCPrime aims to provide effective treatments for hematological cancers, including Multiple […]
